Posted by Michael Wonder on 22 Nov 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia (final guidance)
22 November 2023 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of adults with chronic lymphocytic leukaemia.
Zanubrutinib is recommended as an option for the treatment of adults with chronic lymphocytic leukaemia.
